Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Inger Braide"'
Autor:
Birgitta Swolin, Göran Zador, Inger Braide, Lise-Lotte Röckert, Erik Hippe, Jan Westin, Ida Lisse, Hans Carl Hasselbalch
Publikováno v:
Leukemialymphoma. 5(1)
Interferon-alpha-2b (IFN) was given to a series of 50 patients with hairy cell leukemia (HCL). The IFN dose for both induction and maintenance was 2.0 × 10(6) IU/m(2) s.c. three times weekly. At 24 months 38 patients remained in the study. The propo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::883b3d86b38b3ee03b443fdcc060a840
https://pubmed.ncbi.nlm.nih.gov/27463206
https://pubmed.ncbi.nlm.nih.gov/27463206
Autor:
Ulla Olsson-Strömberg, Martin Höglund, Magnus Björkholm, Inger Braide, Karin Carlson, Gösta Gahrton, Gunnar Grimfors, Robert Hast, Rickard Lerner, Olle Linder, Per Ljungman, Eva Löfvenberg, Claes Malm, Per-Gunnar Nilsson, Christer Paul, Stig Rödjer, Leif Stenke, Ulf Tidefeldt, Ingemar Turesson, Ann-Marie Uden, Anders Wahlin, Lars Vilen, Ingemar Winqvist, Olle Zettervall, Gunnar Öberg, Bengt Simonsson, null (For The Swedish Cml Group)
Publikováno v:
Leukemia & Lymphoma. 47:1768-1773
The aim of the study was to investigate the feasibility of mobilizing Philadelphia chromosome negative (Ph-) blood stem cells (BSC) with intensive chemotherapy and lenograstim (G-CSF) in patients with CML in first chronic phase (CP1). During 1994-199
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3daeab7df358552087bba2a75856460b
https://doi.org/10.1080/10428190600611117
https://doi.org/10.1080/10428190600611117
Publikováno v:
Leukemialymphoma. 43(12)
Patients with relapsed aggressive lymphoma after high dose chemotherapy have a very poor prognosis and long-term survival is rare. Most patients are not eligible for allogeneic stem cell transplantation in this setting and treatment, therefore, becom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8df63816cffce6addd821ad1b4f988
https://pubmed.ncbi.nlm.nih.gov/12613523
https://pubmed.ncbi.nlm.nih.gov/12613523
Publikováno v:
Leukemia research. 18(8)
In eight patients with previously untreated hairy cell leukemia (HCL), by using 111In-labelled platelets and megakaryocyte quantitation, the splenic platelet pooling and the platelet production rate (P) were evaluated before and during alpha-2b-inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c20b84065aef30584607eea93155c64
https://pubmed.ncbi.nlm.nih.gov/8065159
https://pubmed.ncbi.nlm.nih.gov/8065159
Publikováno v:
Cancer. 70(8)
Background. Hairy cell leukemia (HCL) has been associated with several disease states. In this study, a possible association is reported between HCL and renal cell carcinoma (RCC) and colorectal carcinoma (CRC). Methods. A retrospective study of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4e43e8d4f34a067ec4dbd8eb00474b
https://pubmed.ncbi.nlm.nih.gov/1394039
https://pubmed.ncbi.nlm.nih.gov/1394039
Autor:
Bendt Nielsen, Inger Braide
Publikováno v:
European journal of haematology. 49(4)
Thirty-six HCL patients were treated with 2 x 10(6) U/m2 IFN-alpha-2b three times weekly for 24 months, followed by 12 months of treatment with one of three doses ranging from 0.5 x 10(6) U to 2 x 10(6) U/m2. For most patients the response continued
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9637c78f4393e307e808d39e351cc3ba
https://pubmed.ncbi.nlm.nih.gov/8405334
https://pubmed.ncbi.nlm.nih.gov/8405334